immunocompromised due to treatment
Conditions
Interventions
None listed
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - a rheumatic condition; the subject is treated OR have been treated for at least 3 months with one or more of the following medication: methotrexaat (Emthexate®, Ledertrexate®), leflunomide (Arava®) infliximab (Remicade®), etanercept (Enbrel®), adalimumab (Humira®), Abatacept (Orencia®), rituximab (Mabthera®).) - travelling to a (sub)tropical destination during therapy, OR returning from a (sub)tropical destination within a 3 months period after ending therapy.
Exclusion criteria
Exclusion criteria: - individuals less than 18 years old; - mentally incapacitated persons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To quantify travel-related infectious diseases To measure the consequences of illness with regard to frequency and direct costs of seeking medical care, the type of medical care, and the absence from work. To establish efficacy of pre-travel vaccinations by determination of protective serum antibody titres against hepatitis A, DTP and polysaccharide Vi of Salmonella typhi. | — |
Secondary
| Measure | Time frame |
|---|---|
| To develop evidence-based guidelines for the prevention of health problems in the immunocompromised individuals treated with MTX and / or immunosuppressive biologicals because of RA (or other medical conditions). To quantify costs of travel advice and direct costs of seeking medical care and number of day*s absence from work. | — |
Countries
Netherlands
Outcome results
None listed